Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-Induced Hypertension in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2016.12.016
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Elsevier BV

Related search

Hypertension as Predictor of Sunitinib Treatment Outcome in Metastatic Renal Cell Carcinoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2011English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

Sunitinib-Associated Hypertension and Neutropenia as Efficacy Biomarkers in Metastatic Renal Cell Carcinoma Patients

British Journal of Cancer
Cancer ResearchOncology
2015English

Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2015English

Angiogenesis Genotyping in the Selection of First-Line Treatment With Either Sunitinib or Pazopanib for Advanced Renal Cell Carcinoma

Oncotarget
Oncology
2016English

Pcn94 - Cost-Effectiveness of Cabozantinib Versus Sunitinib or Pazopanib as First-Line Treatment of Patients With Advanced Renal Cell Carcinoma in the Uk

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

Oncologist
Cancer ResearchMedicineOncology
2019English

A Rare Case of Sunitinib-Induced Rhabdomyolysis in Renal Cell Carcinoma

Case Reports in Oncological Medicine
Oncology
2018English

Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy